The drug, DP-b99, is undergoing a Phase III clinical trial.
D-Pharm Ltd. (TASE: DPRM) has obtained US Food and Drug Administration (FDA) fast-track approval for its treatment for ischemic strokes. The drug, DP-b99, is undergoing a Phase III clinical trial.
D-Pharm president and CEO Alexander Kozak said that the fast track approval proved that the company had significant potential.
D-Pharm's share price rose 4.3% by mid-afternoon to NIS 19.55, giving a market cap of NIS 345 million.
Published by Globes [online], Israel business news - www.globes-online.com - on April 14, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011